© 2021 MJH Life Sciences and Neurology Live. All rights reserved.
© 2021 MJH Life Sciences™ and Neurology Live. All rights reserved.
Recommendations for appropriate treatment selection and use of high efficacy therapies as treatment for relapsing-remitting multiple sclerosis.
April 19th 2021
Patricia K. Coyle, MD, highlights revisions to the McDonald diagnostic criteria for multiple sclerosis and emphasizes why health care professionals need to start referring to the criteria in a more standard fashion.
Clyde E. Markowitz, MD, comments on the growing role of magnetic resonance imaging to help diagnose multiple sclerosis and highlights characteristics of lesions he looks at during a diagnostic evaluation.
April 26th 2021
An overview of the clinical subtypes of multiple sclerosis and factors that help neurologists distinguish between each type for an appropriate diagnosis.
The rationale for initiating aggressive therapy early on to treat patients who present with relapsing-remitting multiple sclerosis.
May 3rd 2021
Dr Patricia K. Coyle, of the Stony Brook Neurosciences Institute, comments on her approach to selecting first-line therapy to treat relapsing-remitting multiple sclerosis, explaining how she selects between a lower-risk or high-efficacy therapy.
Robert Fox, MD, of the Cleveland Clinic, comments on the advantage of starting treatment with a high-efficacy therapy for relapsing-remitting multiple sclerosis and explains his approach to counseling patients when selecting treatment.
May 10th 2021
An overview of high-efficacy therapies available to treat patients with relapsing-remitting multiple sclerosis.
Impressions of exam results and the prognosis for a 35-year-old man who presents with progressive numbness and weakness in his left arm and leg.
May 17th 2021
Implications for initiating treatment with a high-efficacy therapy for a 35-year-old man who presents with progressive numbness and weakness in his left arm and leg.
The rationale for treating patients with relapsing multiple sclerosis with ofatumumab based on data revealed by the ASCLEPIOS I and ASCLEPIOS II trials.